Our top pick for
Building a portfolio
Genprex, Inc is a biotechnology business based in the US. Genprex shares (GNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Genprex employs 12 staff and has a market cap (total outstanding shares value) of USD$195.2 million.
|52-week range||USD$1.95 - USD$7.72|
|50-day moving average||USD$5.0026|
|200-day moving average||USD$4.1837|
|Wall St. target price||USD$6.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.755|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-64.33%|
|Return on equity TTM||-105.73%|
|Market capitalisation||USD$195.2 million|
TTM: trailing 12 months
There are currently 3.5 million Genprex shares held short by investors – that's known as Genprex's "short interest". This figure is 9.6% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Genprex shares can be evaluated.
Genprex's "short interest ratio" (SIR) is the quantity of Genprex shares currently shorted divided by the average quantity of Genprex shares traded daily (recently around 1.1 million). Genprex's SIR currently stands at 3.08. In other words for every 100,000 Genprex shares traded daily on the market, roughly 3080 shares are currently held short.
However Genprex's short interest can also be evaluated against the total number of Genprex shares, or, against the total number of tradable Genprex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genprex's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Genprex shares in existence, roughly 80 shares are currently held short) or 0.09% of the tradable shares (for every 100,000 tradable Genprex shares, roughly 90 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genprex.
Find out more about how you can short Genprex stock.
We're not expecting Genprex to pay a dividend over the next 12 months.
Over the last 12 months, Genprex's shares have ranged in value from as little as $1.95 up to $7.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genprex's is -0.8305. This would suggest that Genprex's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Genprex has bucked the trend.
Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.